8-K: BioRestorative Therapies Secures $1M Loan and Board Shakeup

BioRestorative Therapies, Inc. entered into a $1 million revolving loan agreement with Bowery Group LLC, resulting in the resignation of three directors and the appointment of three lender-designated board members.

Summary

• BioRestorative Therapies, Inc. entered into a $1,000,000 revolving loan agreement with Bowery Group LLC on June 10, 2026.
• The loan bears an interest rate of 12% per annum, with a default rate of 16%.
• The loan matures on the first anniversary of the closing date.
• Proceeds are intended for general corporate purposes, including financing a Qualified Public Equity Offering.
• Three directors resigned, and three new directors designated by the lender were appointed to the board.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a sign of financial distress, as the company has resorted to high-interest debt and significant board restructuring to secure necessary operating capital.

Positives

• Secured $1,000,000 in liquidity to support general corporate operations and potential public equity offerings.
• Provides a revolving credit facility allowing for reborrowing of repaid amounts up to the maximum limit.

Negatives

• Significant board turnover with the resignation of three directors and the appointment of three lender-designated directors.
• High interest rate of 12% per annum, increasing to 16% in the event of default.
• The loan agreement includes restrictive covenants that limit the company's ability to incur additional debt or pay dividends.
• The lender has the right of first refusal on any subsequent debt financing.

Risks

• Potential for automatic resignation of lender-appointed directors if specific financing milestones are not met by July 17, 2026, or August 10, 2026.
• Risk of default if the company fails to meet payment obligations or breaches covenants.
• The company's financial statements as of December 31, 2025, include a going concern qualification.
• The lender has sole discretion to withhold loan drawdowns if an event of default is continuing.

Future Outlook

The company is committed to using the loan proceeds to finance a Qualified Public Equity Offering of at least $5,000,000 and potentially a Required Additional Financing of at least $10,000,000.

Management Comments

• The company has appointed three new independent directors designated by the lender to the board.

Industry Context

StockSavvy.ai notes that this transaction reflects a common trend among small-cap biotech firms facing liquidity constraints, where lenders often demand board representation and restrictive covenants in exchange for capital.

Comparison to Industry Standards

• The 12% interest rate is consistent with high-cost bridge financing often utilized by micro-cap companies.
• The inclusion of lender-designated board members is a standard, albeit aggressive, condition in distressed or liquidity-constrained financing arrangements.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders may face dilution if the required public equity offerings are executed.
• Creditors gain a secured position via the loan agreement.
• Management faces increased oversight from lender-appointed board members.

Next Steps

• Consummate a Qualified Public Equity Offering.
• Manage ongoing compliance with loan covenants.
• Integrate new board members into audit, compensation, and nominating committees.

Key Dates

Recommendation

The company is in a precarious financial position requiring immediate capital, which has been secured at a high cost and at the expense of board control. Investors should wait for evidence of successful equity financing before considering a position.

Keywords

BioRestorative Therapies, BRTX, Revolving Loan Agreement, Corporate Governance, Board Appointment, Debt Financing, Nasdaq